Fexuprazan vs esomeprazole for endoscopic submucosal dissection-induced gastric ulcer healing: A double-blind randomized controlled trial
World Journal of Gastroenterology · 2027-01-14 · 33 (2)
DOI: 10.3748/wjg.124419 ↗Abstract
BACKGROUND Endoscopic submucosal dissection (ESD) induces large artificial gastric ulcers requiring acid-suppressive therapy, but high-quality evidence comparing potassium-competitive acid blockers (P-CABs) with proton pump inhibitors is limited. We hypothesized that fexuprazan, a novel P-CAB, would achieve a higher complete healing rate of ESD-induced gastric ulcers than esomeprazole. AIM To evaluate the efficacy and safety of fexuprazan vs esomeprazole in the healing of ESD-induced gastric ulcers. METHODS In this multicenter, double-blind, double-dummy, parallel-group superiority randomized controlled trial, patients undergoing ESD for gastric neoplasms received fexuprazan 40 mg or esomeprazole 40 mg once daily for 8 weeks. The primary endpoint was the complete healing rate at 8 weeks, analyzed in both modified intention-to-treat (mITT) and per-protocol (PP) populations. Secondary endpoints included the ulcer shrinkage rate and delayed bleeding. The model-estimated time to a 99% reduction in ulcer area was compared as an exploratory endpoint. RESULTS Of 132 randomized patients, 128 received at least one dose of study medication and were included in the mITT analysis; 107 were included in the PP analysis. In the PP analysis, the 8-week complete healing rate was significantly higher with fexuprazan [90.2% vs 75.0%; risk difference (RD): 15.2%, 95% confidence interval (CI): 1.2-29.2; P = 0.040]; the mITT analysis showed a directionally consistent but non-significant difference (73.4% vs 65.6%; RD: 7.8%, 95%CI: -8.1 to 23.7; P = 0.337). Ulcer shrinkage rates at 4 weeks and 8 weeks were significantly greater with fexuprazan (both P = 0.049). In exploratory analysis, the model-estimated time to a 99% reduction in ulcer area was shorter with fexuprazan (40.31 days vs 47.22 days; P = 0.045), particularly among patients with large baseline ulcers (≥ 800 mm2). Safety was comparable between groups. CONCLUSION In the pre-specified PP analysis, fexuprazan achieved a significantly higher 8-week complete healing rate than esomeprazole, with comparable safety. Exploratory analysis suggested shorter model-estimated healing time in large ulcers, warranting larger trials.
EUVIMED